Abstract Stroke is one of the leading causes of death and disability worldwide. Current treatment strategies for ischemic stroke primarily focus on reducing the size of ischemic damage and rescuing dying cells early after occurrence. To date, intravenous recombinant tissue plasminogen activator is the only United States Food and Drug Administration approved therapy for acute ischemic stroke, but its use is limited by a narrow therapeutic window. The pathophysiology of stroke is complex and it involves excitotoxicity mechanisms, inflammatory pathways, oxidative damage, ionic imbalances, apoptosis, angiogenesis, neuroprotection, and neurorestoration. Regeneration of the brain after damage is still active days and even weeks after a stroke occurs, which might provide a second window for treatment. A huge number of neuroprotective agents have been designed to interrupt the ischemic cascade, but therapeutic trials of these agents have yet to show consistent benefit, despite successful preceding animal studies. Several agents of great promise are currently in the middle to late stages of the clinical trial setting and may emerge in routine practice in the near future. In this review, we highlight select pharmacologic and cell-based therapies that are currently in the clinical trial stage for stroke.
Introduction
The only treatment for ischemic stroke, recombinant tissue plasminogen activator (rt-PA), focuses on recanalization to reduce the size of ischemic damage [1, 2] . There are at least two other major categories of investigational therapies that are currently under development for ischemic stroke, which are: 1) neuroprotection and 2) neurorecovery approaches. Cerebral ischemia activates a cascade of biochemical events that ultimately lead to the death of brain cells. More than 20 years of research has focused on discovering and developing so-called neuroprotective agents that might intervene in this ischemic cascade. Thus far, no protective agent has been shown to improve outcome in phase III clinical trials, but newer approaches continue to be investigated. After the infarct has developed, recovery of motor and cognitive function occurs to a variable degree through a number of pathways, including recruitment of existing but latent connections and development of new neurons and neural connections [3] [4] [5] [6] [7] . The regeneration of the brain after damage is still active days and even weeks after the stroke occurs, which might provide a second window for treatment [8] . Therefore, neurorecovery approaches are being developed that promote the repair of disrupted neural networks during the subacute and chronic phase of ischemic stroke [9] . This review covers pharmacological and cell-based strategies under investigation that fall into the category of neuroprotection, neurorecovery, or both. We focus our discussion on neuroprotective agents that are currently in clinical trials.
Neuroprotection

Hypothermia
The impact of cold temperature on the human body has been studied by clinicians for long time. Hippocrates [10] advocated packing bleeding patients in snow and ice. Approximately 180 years ago, Baron Dominique-Jean Larrey was the first to realize that tissues could recover from low temperatures. He realized that rapid rewarming of hypothermic tissues led to more severe frostbite and gangrene, and hence developed rewarming strategies to salvage very cold body tissues [11, 12] . Hypothermia is one of most promising treatment strategies for acute ischemic stroke. Mild hypothermia is an established neuroprotectant in the laboratory, showing remarkable and consistent effects across multiple laboratories and models of brain injury. It has been shown to improve neurological outcome in comatose survivors of cardiac arrest and neonatal hypoxia ischemia, and it is increasingly being used by many centers for these conditions [13] [14] [15] . However, hypothermia remains poorly understood as a therapy for stroke.
Mechanisms of Neuroprotective Effects of Hypothermia: Supportive Animal Data
Animal models of focal or global cerebral ischemia have suggested that hypothermia confers protection against ischemia or reperfusion injury through multiple mechanisms. Brain protection from hypothermia is associated with preserved metabolic stores, reduced blood flow, prevention of glutamate release, reduced generation of excitotoxins, improved cellular ion handling and pH balance, decreased inflammation, decreased apoptosis, and alterations in gene expression [16] [17] [18] [19] [20] [21] [22] [23] [24] . Activation of peripheral leukocytes and brain resident microglia also occurs after brain injury, and mild hypothermia has been shown to inhibit this activation [25, 26] . Suppression of this activation could be explained by the observation that hypothermia inhibits the pro-inflammatory transcription factor NFkB [27] [28] [29] . Hypothermia also appears to upregulate cell survival pathways, such as activating the Akt pathway [30, 31] and increasing trophic factor expression [32, 33] . In a systematic review and meta-analysis of animal studies of focal cerebral ischemia, including data obtained from a total of 3,353 animals, hypothermia reduced infarct size by 44% (95% confidence interval, 40-47%) [34] . Thus, hypothermia has the potential to affect multiple aspects of cell physiology.
Hypothermia in Ischemic Stroke: Current Clinical Literature
A few clinical studies of mild hypothermia in acute ischemic stroke have been published or are ongoing [35, 36] , and have collectively shown feasibilty, although not completely without complications [37] [38] [39] [40] [41] [42] [43] [44] [45] (Table 1) . A significant challenge is that stroke patients are generally awake (not having endotracheal intubation), and the affected vessel often remains occluded for days or indefinitely in the absence of reperfusion therapies. Similar to what has been encountered in the cardiac arrest and brain injury studies, attaining and maintaining the target temperature is challenging. Another issue is the rebound increased intracranial pressure experienced during rewarming, a phenomenon not well studied in laboratory models [37] . A few clinical studies have used intravascular cooling devices to cool acute stroke patients. In the Cooling for Acute ischemic Brain Damage (i.e., COOL-AID) trial, a randomized pilot feasibility study using endovascular device, most patients tolerated hypothermia, and the clinical outcomes were similar in both the hypothermia group as well as in standard medical management group. There was a suggestion of reduced lesion growth on diffusion-weighted imaging in patients receiving hypothermia. The International Cooling in the Treatment of Stroke (ICTuS) trial [42] , nonrandomized clinical trial using a different intravascular cooling device, also addressed administration of rt-PA to improve chances of recanalization followed by hypothermia. The Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke (ICTuS-L) study [43] , a randomized multicenter trial of hypothermia and rt-PA in acute stroke patients, is the most recent study of catheter-based cooling. In this study, a total of 58 patients were randomized, 30 to normothermia and 28 to hypothermia at 33°C for 24 hours. In the hypothermia group, 24 patients received rt-PA. Cooling was well tolerated and did not affect the occurrence or severity of brain hemorrhage in patients given rt-PA. There were no differences in 90-day outcomes, although the study was not powered to determine efficacy. Pneumonia was the main adverse event that occurred more frequently in cooled patients. Overall, these patients tolerated cooling well, and the incidence of cerebral hemorrhage did not increase. Thus, hypothermia is feasible in ischemic stroke patients, but its benefit is not yet known.
Optimal Cooling Hypothermia can be classified based on the depth of cooling from a normal body temperature of 37 to 38°C: mild (32-35°C), moderate (28-32°C), and deep hypothermia (<28°C). Animal studies of stroke and hypothermia have demonstrated that even modest cooling has considerable potential as a neuroprotective strategy, and the extent of neuroprotection is similar whether the temperature is reduced to 34°C or 25°C. The depth of cooling seems to be a less critical factor, provided that brain temperature is lowered below 35°C. Side effects of hypothermia appear to occur more frequently with each degree of Celsius reduction in temperature. Temperature reductions to 35°C have been shown to be feasible and safe with surface cooling in awake, acute ischemic stroke patients, in combination with meperidine to treat shivering [46] . The ICTuS-L trial [43] found intravascular cooling to 33°C in combination with intravascular thrombolysis safe and feasible.
Future Directions
Currently, hypothermia suffers from lack of technological development, and cooling technologies are in their infancy. Current technologies provide reasonable control of body temperature, but they may cool patients too slowly to optimally target intra-ischemic treatment window. A phase 2/3 efficacy trial of mild endovascular cooling has just begun to date. Focal cooling is likely to be advantageous for stroke because it seems likely that a reduction of local tissue temperature is all that is required to confer protection and minimize the time to target temperature and adverse effects, such as shivering and infection. A few preclinical studies have shown that neurotensin and its analogs, 3-iodothyronamine and hydrogen sulfide, can all decrease body temperature to the depth and for durations previously shown to be neuroprotective in animal models [47] .
Albumin
Human serum albumin is a major component of plasma, cerebrospinal fluid, and interstitial fluid, and an important circulating carrier, which is synthesized mainly in the liver. The multiple beneficial effects of higher serum albumin levels include binding to free fatty acids, metabolites and drugs, providing energy to neurons for metabolism and repairing injured neurons, supporting endothelial cell function by inhibiting apoptosis, reversal of blood-element aggregation, and exerting antioxidant effects [48] [49] [50] .
Mechanisms of Neuroprotective Effects of Albumin Therapy: Supportive Animal Data
The neuroprotective effects of human albumin have been demonstrated in models of acute cerebral ischemia, including transient and permanent middle cerebral artery occlusion models or global ischemia models [48, [51] [52] [53] [54] . It has also been shown to improve cerebral perfusion [54, 55] , to normalize changes in diffusion-weighted magnetic resonance imaging [53] , to reverse postischemic microvascular stasis [56] , and to contribute to the systemic mobilization and supply of free fatty acids to the postischemic brain [57] . These studies used albumin doses of 1.25 g/kg to 2.5 g/kg and found them to be markedly neuroprotective, with a therapeutic window of 4 to 5 hours [48] . The potential ability of albumin to maintain the permeability of microvasculature has been suggested as the pathophysiological basis for its possible synergistic effect with rt-PA. Several specific albumin-binding sites are expressed by microvascular endothelial cells on their surface [58] [59] [60] . Albumin binds to endothelial glycocalyx and maintains the normal permeability of microvessel walls, serving as a carrier for various molecules through its capability of transcytosis across endothelium [59, 61, 62] . Tang et al. [63] demonstrated significantly reduced blood brain barrier permeability in a transient focal ischemia rat model when treated with rt-PA along with albumin, and hence significantly attenuating deleterious effects of rt-PA. Albumin is also an important inhibitor of platelet aggregation [64] [65] [66] . Albumin also increases the production of the anti-aggregatory prostaglandin (PGD2) from cyclic endoperoxides [65] . The use of albumin also binds plateletactivating factor with high affinity [66, 67] , and decreases platelet-activating factor induced responses in platelets [68] .
The coating of thrombogenic surfaces with S-nitrosylated albumin reduces platelet adhesion and aggregation, which is an effect attributable to both the direct antiplatelet actions of nitric oxide and the anti-adhesive properties of albumin itself [64] . Another protective mechanisms exerted by high-dose albumin infusion in ischemic stroke may be scavenging of the accumulating lysophosphatidylcholine and preventing its pro-inflammatory and proapoptotic effects [52, 69] .
Clinical Literature The Albumin in Acute Stroke (ALIAS) pilot clinical trial [70] found that 25% human albumin (in doses ranging up to 2.05 g/kg) was well tolerated by patients with acute ischemic stroke without major doselimiting complications, and rt-PA therapy did not affect the safety profile of albumin. Based on these results, a large, randomized, double-blind, placebo-controlled, multicenter clinical trial designed to ascertain the therapeutic efficacy of albumin in acute ischemic stroke within 5 hours from onset is currently ongoing to date.
Magnesium
Magnesium is an endogenous calcium antagonist that regulates vascular tone, blood pressure, and cell membrane function. There is extensive experience with magnesium use, largely in pre-eclampsia/eclampsia, which confirms its safety and tolerability. There are a number of potential mechanisms by which magnesium may act, including increased regional blood flow to ischemic brain areas [71] , nonspecific antagonism of all subtypes of voltagesensitive calcium channel [72] , noncompetitive blockade of the N-methyl-D-aspartate acid subclass of glutamate receptor [73] [74] [75] [76] [77] [78] , presynaptic glutamate release inhibition [79] [80] [81] [82] , potentiation of adenosine action, enhanced recovery of cellular energy metabolism after ischemia [83, 84] , and improved mitochondrial calcium buffering [85] . The neuroprotective effects of magnesium have been found in many models of ischemic cerebral damage [86] [87] [88] . In permanent or transient middle cerebral artery occlusion models in rodents, systemically administered magnesium reduced infarct volume [87, 88] . In embolic middle cerebral artery occlusion, magnesium significantly reduced infarct volume and improved neurological outcome even when given 6 hours after onset of ischemia [78] . A number of small clinical trials of magnesium that were undertaken, initially established its safety for use in acute stroke [89, 90] . Several of these small pilot trials in stroke have reported reduced proportions of magnesium-treated patients being dead or disabled at 3 to 6 months [89] [90] [91] [92] [93] [94] . The odds ratio for death or disability in a systematic review of these pilot trials was 0.73, but with a wide 95% confidence limit (0.38, 1.41) [95] . However, the Intravenous Magnesium Efficacy in Stroke (IMAGES) trial using a 12-hour treatment window found magnesium to be largely ineffective, with a benefit in lacunar strokes only [94, 96] . In the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial [97] , no adverse events related to field administration of magnesium were observed. Because of the concerns that the Intravenous Magnesium Efficacy in Stroke (IMAGES) trial applied an unrealistically long enrollment period, the FAST-MAG efficacy trial was established and is ongoing [98] . The FAST-MAG trial uses pre-hospital randomization and treatment in the field. More than 1000 patients have been randomized to date, with more than 70% patients treated within the first hour of symptoms, which is by far the fastest treatment in any stroke trial ever accomplished. Table 2 summarizes the clinical trials of magnesium in ischemic stroke.
Neuroprotection and Neurorecovery
Granulocyte Colony Stimulating Factor
Hematopoietic growth factors, also known as colony stimulating factors, modulate and recruit the lineagespecific differentiation of bone marrow stem cells leading to generation of circulating red cells, white cells, and platelets, and their mobilization to peripheral blood. Interestingly, data from experimental studies suggest that colony stimulating factors could improve stroke outcome by reducing stroke damage and improving post-stroke brain repair [99] . As an example, granulocyte colony stimulating factor (G-CSF) is a growth factor of approximately 20 kDa that acts on hematopoietic CD34 + stem cells to regulate neutrophil progenitor proliferation and differentiation, and is routinely used for the treatment of chemotherapy-induced neutropenia, or for the purpose of mobilizing and harvesting peripheral blood stem cells for subsequent autologous or allogenic infusion. In rat and mice models of ischemic stroke, G-CSF reduces stroke lesion volume at various doses [100] , even in the presence of thrombolysis [101] [102] [103] . G-CSF protects neurons against glutamate-induced excitotoxicity [100] , induces functional recovery by stimulating neuronal progenitor cells [104, 105] , and promotes angiogenesis [105] [106] [107] and neurogenesis [105, 107, 108] . G-CSF also reduces inflammatory responses by suppressing inducible nitric oxide synthase and other inflammatory mediators, such as interleukin 1-β [109] [110] [111] , as well as stem cell mobilization to the brain [105] . G-CSF is released in response to cerebral ischemia and its effects are probably mediated by a special neuronal G-CSF receptor, because it passes even the intact blood brain barrier, and therefore reaches injured brain regions [100, 108] . However, G-CSF has also been reported to lead to impaired behavioral function [112] , and may be of no benefit when given in the chronic phase of stroke [113] or in global ischemic models [114] .
The promising results in animal models led to the implementation of phase I/II randomized clinical trials [115] [116] [117] [118] [119] as summarized in Table 3 . Together, these trials show that G-CSF was well tolerated and appeared to be safe, and significantly increased white cell counts. Larger clinical trials aiming at confirming safety and demonstrating efficacy of G-CSF are underway. Data from these completed and ongoing trials will inform whether larger phase III trials of G-CSF are warranted.
Citicoline
Citicoline is a naturally occurring endogenous compound that was originally identified as the key intermediary in the biosynthesis of phosphatidylcholine by Kennedy [119] in 1956. Also known as CDP-Choline, citicoline is an essential precursor in the synthesis of phosphatidylcholine, a key cell membrane phospholipid. Citicoline has been increasingly recognized as a neuroprotectant that may act both in early and late stages of ischemic damage, resulting in a plethora of experimental and clinical trials assessing safety and efficacy of its use as a treatment for stroke. Citicoline neuroprotective effects may occur through its ability to improve phosphatidyl choline synthesis in the injured brain [120] . Citicoline stabilizes and repairs membranes [121] ; favors the synthesis of nucleic acids, proteins, acetylcholine, and other neurotransmitters; decreases free radical formation; inhibits free fatty acid release [122, 123] ; and has anti-apoptotic effects [124] . Due to these effects, citicoline may simultaneously inhibit different steps of the ischemic cascade, thus protecting the targets against early and delayed mechanisms responsible for ischemic brain injury, as well as facilitate recovery by fostering synaptic outgrowth and increased neuroplasticity [125] . Studies in animal models of ischemia and hypoxia report that citicoline decreases neurological deficits, and improves behavioral performance of learning and memory tasks [126] . There have also been preclinical studies reporting enhanced efficacy when citicoline was administered along with or following intravenous thrombolysis [127] [128] [129] , and along with other potential neuroprotective therapies, such as mild hypothermia [130] . Multiple, randomized clinical stroke trials have investigated citicoline and reported that administration of citicoline was effective early in the post-ischemia recovery process, as demonstrated by improved level of consciousness [131] , and improvements in the modified Rankin score [132] . Oral treatment with citicoline within the first 24 hours after onset of moderate to severe stroke was reported to increase the probability of complete recovery at 3 months in a meta-analysis of 4 randomized clinical trials, with the highest favorable response observed in the 2000-mg dose group [133] . This was followed by a comprehensive metaanalysis of 8 randomized clinical trials of citicoline, which enrolled 2063 patients reporting that treatment with citicoline was associated with absolute reductions of 10 to 12% in rates of long-term death and disability, although no individual trial demonstrated treatment benefit unequivocally [134] . Pooled analysis of 2 citicoline trials collecting serial magnetic resonance imaging data similarly suggested a dose-dependent reduction in infarct growth [135] . The safety of citicoline has also been established in many trials; there is no difference in side effects between the placebo and citicoline groups [132] . Citicoline is currently approved in many countries for use in stroke, head trauma, and other neurological disorders. An international, multicenter, phase III randomized trial (International Citicoline Trial on Acute Stroke [ICTUS]) comparing the efficacy of a 2-gram daily dose of citicoline started within 24 hours of ischemic stroke onset and continued for 6 weeks against a placebo is currently ongoing to date.
Neurorepair and Neurorestoration: Cell-Based Therapies
The adult brain responds to acute injuries, such as stroke, by inducing neural progenitor proliferation, which might be an endogenous attempt at self-repair, a process that is active for days and even weeks after a stroke and is altered by several endogenous and exogenous modulators. Functional recovery may occur in a small brain injury using rehabilitation measures, but for large ischemic strokes the restoration may require new synaptic connections within and away from the damaged tissue. Functional neuroimaging has demonstrated changes in a number of features of brain G-CSF = granulocyte-colony stimulating factor; ICTuS = International Citicoline Trial on Acute Stroke; MCA = middle cerebral artery; SAEs = serious adverse events; NIHSS = National Institutes of Health Stroke Scale function after stroke, including global derangement in brain function and behavior in the initial hours/days, followed by a period of growth characterized by demonstrable structural and functional changes in both the ipsilateral and contralateral hemispheres that last several weeks, that is finally followed by pruning and reduction in functional over-activation as well as establishment of a static pattern of brain activity and behavior. This growth-related period may be a key target for certain restorative therapies during the early phase of acute stroke [136] . Hence, the treatment strategies targeting the prospects of repairing the neuron system, either by modulating endogenous neurogenesis or using exogenous stem cells to replace the lost cells or support the remaining cells in the post-ischemic brain, provide a unique approach for brain repair and restoration of function after a devastating stroke. The potential application for stem cell therapy is vast, but development for its use in ischemic stroke is still in its infancy. Despite a limited understanding of their mechanism of action, a plethora of experimental and clinical trials assessing their use in stroke have been already performed.
Cell Types and Their Sources for Stroke Therapy
Stem cells have the capacity to self-renew and differentiate into different cell types, including neurons, astrocytes, and endothelial cells. A number of cell sources for stem cell transplantation are available, and these can be categorized into several dimensions: exogenous or endogenous sources of cells; embryonic, fetal, or adult derivation; neural or nonneural origin; and pluripotential, which can divide indefinitely; or multipotential, which usually regenerate their "own tissue" but have the ability to trans-differentiate into other tissue cell types. The cell types that have been tested in preclinical transplantation studies in the stroke model are summarized in Table 4 .
Embryonic Stem Cells
Fetal tissue has been the major source of cell transplantation in animal models of stroke. Embryonic stem cells (ESCs) are self-renewing and multipotent cells with unlimited expandability derived from the inner cell mass of the pre-implantation blastocyst [137] . The potential drawback of these cells is that they tend to develop a heterogeneous mix of neural precursors and differentiated neurons [138] , and have potential for malignant transformation producing teratomas and highly malignant teratocarcinomas [139, 140] . Due to this potential risk, there have not been extensive reports of transplanting undifferentiated ESCs in stroke animals [141, 142] . Xenologous transplantation has been suggested to exert a tumor-suppressive effect on ESCs [141] . Another possible solution to overcome these drawbacks is to differentiate ESCs in vitro first, which seems to greatly reduce their tumorigenic potential [142] . Recent developments in the induction of pluripotent stem cells from somatic adult cells provide a tremendous opportunity for this field [143] [144] [145] to consider an alternative source of pluroipotent cells rather than ESCs. The transplantation of induced pluripotent cells has not been studied in stroke, but if this technique works it would provide the advantage of both generating autologous and specifically engineered stem cells for an individual patient.
Neural Stem Cells
Several studies have explored the possibility of transplanting neural stem cells (NSCs) derived from the subventricular zone in animal stroke models and have reported successful differentiation of these cells into different neurons and glial cell types, with their robust migration to the ischemic area and resultant improvement in functional behavioral tests [146] [147] [148] . An enriched environment appears to improve NSCs migration and functional recovery [149] . These cells can be genetically modified to express certain genes that may facilitate the regeneration process [150] . As an alternative, immortalized neuronal precursor cell lines derived from cultured adult neural tissue offer a ready and unlimited source of cells, thereby reducing ethical concerns in obtaining aborted fetal tissue. Malignant transformation following therapeutic transplantation of this cell type is a key concern for this approach.
Stem Cells Derived from Blood and Bone Marrow
Bone marrow-derived stem cells (BMSCs), umbilical cord blood, and peripheral blood stem cells are alternative sources of stem cells, and their use carries less ethical concerns when transplanted in an autologous manner. Bone marrow and umbilical cord blood are composed of multiple cell types containing hematopoietic and endothelial CD34 + precursor cells and nonhematopoietic mesenchymal stromal (MSC) or CD34 _ cells. A small percentage of BMSCs are multipotent, with the remaining representing more differentiated committed cells [151] . BMSCs have been shown to improve outcome in experimental models of stroke [152, 153] and preserve cognitive function; behavioral improvement has been demonstrated with intracarotid transplantation of MSC [154] and CD133+ cells in rat stroke models [155] , as well as with intravenous administration of umbilical cord stem cells [156, 157] . Autologous BMSCs have been safely harvested from rodents after stroke and documented to migrate to the peri-infarct area, enhance recovery, and modulate the post-ischemic inflammatory response. [158] There are several bone marrow-derived cell types that have greater potential than normal BMSCs, such as multipotent adult progenitor cells [159] , marrow isolated adult multilineage inducible cells [160] , human bone marrow-derived multipotent stem cells [161] , and very small embryonic-like stem cells [162] . These cells are pluripotent and can differentiate into cell types originated from mesenchymal, endodermal and ectodermal layers [163] . When tested in an in vivo stroke model, multipotent adult progenitor cells could significantly enhance functional recovery in stroke animals [164] . Human bone marrowderived multipotent stem cells have been tested in the myocardial animal model with a beneficial outcome [161] . The other bone marrow-derived pleuripotent cell types have not been tested in models of ischemic brain injury to best of our knowledge.
Olfactory Ensheathing Cells
Olfactroy ensheathing cells (OECs) are the cells ensheathing the axons of neurons in the olfactory bulb. These cells share the features of both the Schwann cells and astrocytes [165] . Recently, OECs have been tested in a stroke animal model in which they secreted trophic factors, including stromal-cell derived factor-1 alpha. Rats implanted with OECs showed improvement in both behavioral measurement and functional neuroimaging [166] .
Potential Mechanisms of Stem Cell-Mediated Recovery
Multiple mechanisms have been proposed that may account for the beneficial outcome observed in cell transplantation studies.
Cell Replacement
Multiple studies in animal models of stroke have reported ability of transplanted stem cells to migrate to the ischemic brain area and differentiate into neuronal and glial phenotypes [167, 168] . Furthermore, synaptogenesis and integration into host neuronal circuits have been demonstrated in the host brain, suggesting that the cell replacement might be an achievable goal [169, 170] . However, there is now evidence that neural differentiation is not necessary for the beneficial outcome observed in many types of transplantation-based therapy [171] . Furthermore, neuroprotective effects of peripherally transplanted cells without crossing blood brain barrier have been reported [172] .
Trophic Factor Production
Transplanted cells may produce trophic factors, supporting the survival of existing neurons in the peri-infarct areas [172, 173] , as well as neurogenesis and synaptogenesis [166, 174] . [176, 178] . It is also likely that stem cells play a pivotal role in the regulation of the inflammatory cascade by suppressing the inflammatory response via the production of cytokines and growth factors [179] .
Facilitating Recruitment of Endogenous NSCs
The nonregenerative capability of the injured adult brain has been challenged in recent years and neural plasticity has been observed experimentally in both global and focal brain ischemia in animal models [180] . Under physiological conditions, the subventricular zone NSCs proliferate and migrate along the rostral migratory stream to the olfactory bulb and differentiate into granular interneurons [181] . Furthermore, newly generated neurons migrate toward ischemic boundary regions and differentiate into neurons [182, 183] . There is evidence that, although stroke stimulates these processes, the endogenous response is not enough for recovery of brain function [184] . Transplanted cells may support the survival of newly generated neurons and glial cells by inhibiting apoptosis at injury sites [185] .
Clinical Trials of Cell Transplantation after Ischemic Stroke
There have been no large-scale clinical trials of cell transplantation in stroke. In a recent Cochrane review [186] of 13 studies of stem cells in patients with ischemic stroke, the authors identified only 3 very small randomized control trials, with 2 of them still awaiting clarification, and the third trial randomized 30 patients of middle cerebral artery infarction with persistent neurological deficit 7 days after their stroke to intravenous transplantation of autologous MSCs (n=5), or a control, standard of care group (n= 25). This study reported a statistically nonsignificant functional improvement in treated patients at longer follow-up without adverse cell-related events, demonstrating initial evidence for feasibility in administering ex vivo cultured MSCs [187] . The completed, as well as the currently ongoing, prospective clinical studies investigating stem cell therapy for acute ischemic stroke [188] [189] [190] [191] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] have been summarized in Table 5 .
Future Development of Cell-Based Products as a Potential Treatment of Stroke
Despite availability of large preclinical data suggesting potentially improved clinical outcome with stem cell use in ischemic stroke, limited clinical data exists and many questions remain unanswered. It is vital that future experimental studies are of high quality and have standardized protocols and outcome measures so that they can be fairly compared. Currently, guidelines are being formulated to guide further research into the role of cell-based therapy in both translational and basic research areas [191] .
One possible advantage of treating stroke with stem cells is a potentially wide therapeutic window. The optimal time of administration post-stroke will relate to the microenvironment of the damaged area. That is, should stem cells be administered during the acute phase of stroke at a time when inflammatory responses are maximal or will delayed treatment be effective at a time when scar tissue has formed?
The ideal route of stem cell delivery is also unclear. This has been addressed in one pre-clinical study comparing intrastriatal, intra-ventricular, and intravenous administration of neural precursor cells with all routes resulting in cells targeting the lesion [192] . In contrast, another study assessing intravenous administration of human umbilical cord cells in rats did not detect any evidence of stem cells in the target lesion [176] . The implications of initial trapping of stem cells inside the lungs after intravenous administration on the route, dose, and type of cells used for stem cell therapy also needs to be further evaluated [193, 194] . If intra-cerebral administration proves to be the most effective (although this is probably fraught with more potential risks), then should cells be transplanted directly into the ischemic lesion or distant to it (reducing the chance of damaging vital structures) and relying on spontaneous stem cell migration? [141, 195, 196] Prior trials used intracerebral injections of neural-based cells directly into the peri-infarct area [191, 192] , but an insufficient numbers of patients were studied to draw conclusions about safety. However, there is evolving literature that suggests a direct injection of some types of cells may not be necessary. For example, systemic administration of bone marrow-derived mononuclear cells, which are smaller than purified stem cells, such as mesenchymal stem cells, can pass through the lungs and may enhance recovery from a stroke. These studies support ongoing early stage trials to assess the safety of autologous Mononuclear cells (MNCs) in stroke patients [158, 197] .
Overall, there are multiple sources of exogenous stem cells available, but the cell type that should be transplanted for a given stroke type and size is undetermined. Endogenous stem cell treatment is an attractive alternative, removing the need for immunosuppression. Recent advances offer the possibility to harvest adult terminally differentiated cells and reprogram them into stem cells [143, 145] . Translating this technology to 
Summary
Current treatment strategies in acute ischemic stroke are vessel and blood based. Brain-based therapies, including neuroprotection through blocking the cellular, biochemical, and molecular mechanisms of ischemic injury, and neurorestoration by enhancing neuroplasticity and salvaging peri-infarct areas are potential future therapies that will increasingly complement and enhance current ischemic stroke management. Several agents of great promise are currently in the middle to late stages of clinical trial settings to date, and may emerge in routine practice in the near future.
The most promising interventions providing acute neuroprotection that are being tested in larger clinical trials include hypothermia, magnesium sulfate, citicoline, and albumin.
The most promising therapies enhancing neurorecovery in the subacute phase of stroke include G-CSF, citicoline, and cell-based therapies. 
